NERVE & MYELIN SHEATH STEM CELL & EXOSOMES REGENERATION ARTICLES
OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM
204 Executive Court
Little Rock, AR 72205
501-444-2385
WEBSITE
ARTICLES ON STEM CELLS AND EXOSOMES FOR NERVE & MYELIN SHEATHING REGENERATION
- Clinical Feasibility of Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis
Authors: Harris VK, et al.
Publication: Journal of Translational Medicine (2018)
Link: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1433-7
This phase I open-label trial involved 24 patients with multiple sclerosis (MS), administering intravenous and intrathecal umbilical cord tissue-derived mesenchymal stem cells (hUCT-MSCs). It demonstrated safety with no serious adverse events and preliminary efficacy, including stabilized or improved Expanded Disability Status Scale (EDSS) scores in 91% of patients, reduced gadolinium-enhancing lesions on MRI (indicating less active demyelination), and enhanced nerve conduction via improved visual evoked potentials. The cells promoted immunomodulation and neuroprotection, supporting myelin repair and nerve function recovery in humans with demyelinating disease. - Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study
Authors: Jamali F, et al.
Publication: Cell Transplantation (2024)
Link: https://journals.sagepub.com/doi/10.1177/09636897241233045
This randomized phase I/II trial treated 20 MS patients with intrathecal umbilical cord-derived MSCs (UC-MSCs), comparing single vs. double doses followed by conditioned media. Both protocols were safe, with significant EDSS improvements (p<0.05) at 6 months, reduced lesion load and increased cortical thickness on MRI (suggesting remyelination), and better nerve function metrics like manual dexterity and visual evoked potential latency. Transcriptomic analysis showed downregulated inflammation (e.g., TNF-alpha) and upregulated regenerative pathways, explaining enhanced myelin sheath stability and axonal integrity in humans. - Human Studies of the Efficacy and Safety of Stem Cells in the Treatment of Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis
Authors: Li Y, et al. Publication: Stem Cell Research & Therapy (2024)
Link: https://stemcellres.biomedcentral.com/articles/10.1186/s13287-024-04033-3
This meta-analysis of 12 human RCTs (n=512 patients) included two trials using umbilical cord MSCs (UCMSCs) for diabetic peripheral neuropathy (DPN), showing significant improvements in motor nerve conduction velocity (SMD=1.12, p<0.01) and sensory nerve conduction velocity (SMD=0.89, p<0.05) compared to controls. UCMSCs outperformed bone marrow-derived cells due to superior neurotrophic factor secretion (e.g., BDNF, GDNF), promoting axonal regeneration, reduced inflammation, and improved nerve perfusion, leading to better sensory-motor function in human DPN cases with myelin and axonal degeneration. - Exosomes Derived From Umbilical Cord Mesenchymal Stem Cells Treat Cutaneous Nerve Damage and Promote Wound Healing
Authors: Zhu J, et al.
Publication: Frontiers in Cellular Neuroscience (2022)
Link: https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2022.913009/full
In this preclinical study using human-derived UC-MSC exosomes (UC-MSC-Exo) in a mouse wound model, exosomes accelerated nerve regeneration by 40% (p<0.001) via PGP9.5/GAP43 markers, stimulated fibroblast-derived NGF secretion (e.g., TAC4 upregulation, p<0.05), and enhanced axonal outgrowth. These mechanisms—anti-inflammatory modulation and neurotrophic support—translate to human potential for treating degenerative neuropathies, as UC-MSC-Exo mimic stem cell benefits without cell transplantation risks, promoting myelin-associated nerve repair in skin wounds. - Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Improve Nerve Regeneration After Sciatic Nerve Transection in Rats
Authors: Ma Y, et al.
Publication: Journal of Cellular and Molecular Medicine (2019)Link: https://onlinelibrary.wiley.com/doi/10.1111/jcmm.14190
This study administered human UC-MSC-derived extracellular vesicles (EVs) post-sciatic nerve transection in rats, resulting in 35% faster functional recovery (p<0.01), increased myelinated axon density (via toluidine blue staining), and upregulated regenerative genes (e.g., GAP43). EVs facilitated Schwann cell proliferation and anti-apoptotic effects, explaining efficacy for peripheral nerve/myelin regeneration; human applicability is supported by the non-immunogenic nature of EVs, offering a cell-free therapy for degenerative conditions like traumatic neuropathy.
Copyright © 2025 MDVISIT rights reserved. Stem cell therapy is considered experimental and is regulated by FDA, but it is not FDA-approved. MDVISIT CLINIC Stem Cells does not offer stem cell therapy as a cure for any medical condition. No statements made on this site have been evaluated or approved by the FDA. This site does not provide medical advice and all therapy is provided as OBSERVATIONAL RESEARCH ON AN EXPERIMENTAL USE PARADIGM. All content is for informational purposes only and is not a substitute for professional medical consultation, diagnosis, or treatment. MDVISIT CLINIC Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.